News | February 25, 2026
UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
This marks the first partnership between Pfizer and Cipla in India
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
A triple-action Formula for comprehensive respiratory relief
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Subscribe To Our Newsletter & Stay Updated
